SILO PHARMA, INC. Deferred Revenue
SILO PHARMA, INC. (SILO) had Deferred Revenue of $72.10 thousand as of 2024-03-31, per its 10-Q filed 2024-05-13.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:DeferredRevenueCurrent · last filed 2024-05-13
- 2024-03-31: Deferred Revenue, Current $72.10K.
- 2023-12-31: Deferred Revenue, Current $72.10K.
- 2023-09-30: Deferred Revenue, Current $72.10K.
- 2023-06-30: Deferred Revenue, Current $72.10K.
| Period end | Deferred Revenue, Current | Deferred Revenue, Current as first filed |
|---|---|---|
| 2024-03-31 | $72.10K 10-Q · filed 2024-05-13 | |
| 2023-12-31 | $72.10K 10-Q · filed 2024-05-13 | |
| 2023-09-30 | $72.10K 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $72.10K 10-Q · filed 2023-08-11 | |
| 2023-03-31 | $72.10K 10-Q · filed 2023-05-12 | |
| 2022-12-31 | $72.10K 10-K · filed 2024-03-25 | |
| 2022-09-30 | $72.10K 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $72.10K 10-Q · filed 2022-08-01 | |
| 2022-03-31 | $72.10K 10-Q · filed 2022-05-13 | |
| 2021-12-31 | $72.10K 10-K · filed 2023-03-24 | $68.75K 10-K · filed 2022-03-28 |
| 2021-09-30 | $68.75K 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $68.75K 10-Q · filed 2021-08-13 | |
| 2021-03-31 | $68.75K 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |